See also: Arthritis and HIV
General Information
- HIV and Osteoporosis (AIDSinfo) and Spanish version
- Bone health and HIV disease (Project Inform)
- Osteoporosis (AIDS InfoNet) and Spanish version
- Osteonecrosis (AIDS InfoNet) and Spanish version
- Bone problems & HIV/AIDS – web page from TheBody with links to many fact sheets and articles
- Osteonecrosis – web page from MedlinePlus with basic information and links to other resources
- Osteoporosis – web page from MedlinePlus with basic information and links to other resources
Selected Recent Articles
- Is Bone Density Loss on PrEP Higher Than Previously Believed? (September 2016, Poz)
- PrEP Use May Stunt Bone Growth in Young Men. (September 2016, Poz)
- Osteoporosis and Smoking Raise Fracture Risk in People with HIV. (September 2016, HIV Treatment Alerts/TheBodyPro)
- Kidney and Bone Markers Improve in Patients With Renal Impairment After Switch from TDF to TAF. (August 2016, TheBodyPro)
- Bone Density Decreases More for Individuals Living With HIV in U.S. Study. (August 2016, TheBodyPro)
- Bone loss partially recovers after stopping PrEP, twice-yearly kidney monitoring is enough for most. (July 2016, AIDSmap)
- Switch From TDF to TAF Tied to Better Bone Mineral Density and Bone Markers. (July 2016, TheBodyPro)
- Switching from tenofovir DF to TAF improves bone and kidney safety. (July 2016, AIDSmap)
- No effect of tenofovir on infant bone mineral content in African study. (June 2016, HIV Treatment Bulletin)
- Bone Loss in First Months of HIV Treatment Linked to Immune Reconstitution. (May 2016, TheBodyPro)
- Is There a Simple Solution to HIV Medication-Associated Bone Loss? (April 2016, Poz)
- Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys. (April 2016, AIDSmap)
- Switching to regimen with new form of tenofovir (TAF) improves kidney and bone health markers. (April 2016, Project Inform)
- Low Bone Density Tied to Incident Fracture in Two U.S. HIV Cohorts. (March 2016, TheBodyPro)
- Does Hep C Exposure Raise the Risk of Kidney Disease and Osteoporosis in People With HIV? (March 2016, Poz)
- Maternal use of Viread comparable to zidovudine regarding infant BMC. (February 2016, Healio); abstract from 2016 Retrovirus Conference
- NIH-funded study finds effect of PrEP on bone density is reversible. (February 2016, National Institute of Allergy and Infectious Diseases); related coverage from AIDSmap, BETA Blog, Healio, and Poz
- Switching to emtricitabine/tenofovir alafenamide (F/TAF) maintains viral suppression with better bone and kidney safety. (February 2016, TheBody); related coverage from AIDSmap
- Tenofovir treatment raises the risk of broken bones. (February 2016, AIDSmap)
- High Rate and Progression of Low Bone Mineral Density in U.S. HIV Group. (February 2016, TheBodyPro)
- Starting HIV Treatment Earlier Translates to More Bone Loss. (November 2015, Poz)
- Does Truvada as PrEP Stunt Bone Growth in Young Men? (October 2015, Poz)
- START sub-study shows more bone loss with earlier HIV treatment. (October 2015, AIDSmap)
- Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety. (October 2015, AIDSmap)
- Lower bone mass in infancy linked to HIV medication. (October 2015, Healio)
- Bone Density Drops About 1% in HIV-Negative MSM and Transgender Women on PrEP. (September 2015, TheBodyPro)
- HIV Increases Bone Fracture Risk by 32% in Middle-Aged U.S. Women. (September 2015, TheBodyPro)
- Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety. (September 2015, TheBodyPro)
- Bone loss slows, but continues long-term in HIV-positive people on antiretroviral therapy. (September 2015, AIDSmap)
- Daily PrEP lowers hip, spine BMD in HIV-seronegative patients. (August 2015, Healio)
- Updated Tenofovir Is Safer for Bones and Kidneys. (July 2015, Poz)
- Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health. (July 2015, AIDSmap)
- Isentress causes less bone density loss than PIs. (May 2015, Healio)
- Truvada PrEP causes only mild loss of bone mineral density. (May 2015, AIDSmap)
- Joint Pain Flares Among People With HIV, Hepatitis C or Both. (May 2015, Hepmag)
- Truvada as PrEP Leads to Small Initial Decrease in Bone Density. (April 2015, Poz)
- FRAX fracture prediction tool underestimates fracture risk in people with HIV. (March 2015, AIDSmap)
- New form of tenofovir TAF looks to be easier on bone and kidney health to the current TDF. (March 2015, Project Inform)
- Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation. (February 2015, AIDSmap)
- New Guidelines for Bone Care Among People With HIV. (February 2015, Poz)
- Screening for bone fracture risk should be routine for over-40s with HIV, new guidelines recommend. (February 2015, AIDSmap)
- Significantly Less BMD Loss With HIV Therapy That Doesn’t Contain Tenofovir/Emtricitabine. (October 2014, TheBodyPro)
- Preventing and Treating HIV-Associated Bone Disease. (October 2014, TheBodyPro)
- HIV/HCV-Coinfected Individuals at Greater Risk of Osteoporosis and Fractures. (August 2014, TheBodyPro)
- Bone mineral density linked to inflammatory markers in HIV positive people who are ART naïve. (August 2014, HIV i-Base)
- People With Both HIV & Hep C Have Raised Risk of Bone Loss. (July 2014, Poz)
- HIV/HCV co-infection associated with increased risk of osteoporosis and fractures. (July 2014, AIDSmap)
- Viread During Pregnancy Lowers Babies Bone Density. (March 2014, Poz)
- Spleen and Bone Marrow May Be Key Players in Arterial Inflammation with HIV. (March 2014, NATAP)
- Vitamin D/Calcium Supplements Reduce Bone Loss by 50% When Starting EFV/TDF/FTC. (March 2014, NATAP)
- Calcium and High-Dose Vitamin D Supplements Cut Bone Loss by Half. (March 2014, Beta Blog)
- HIV Drug Linked to Low Bone Density in Babies. (March 2014, MedPage Today)
- Newborns Exposed to TDF in Utero Have Lower Bone Mineral Content in U.S. (March 2014, NATAP)
- Testosterone Falls No More With Than Without HIV Over 6 Years in MACS. (March 2014, NATAP)
- HIV increases fracture risk, say Danes. (February 2014, AIDSmap)
- No brittle bones. (Winter 2014, Positively Aware)
- High prevalence of osteoporosis and osteopenia in young men with HIV. (October 2013, AIDSmap)
- HIV-positive people not on antiretrovirals are prone to inflammation-related bone loss. (October 2013, AIDSmap)
- New Tenofovir Has Lower Dose, Is Kinder to Kidneys and Bones. (September 2013, Poz)
- New tenofovir formulation works equally well with less effect on kidneys and bones. (September 2013, AIDSmap)
- Low baseline CD4 cell count associated with greater bone loss after starting HIV therapy. (August 2013, AIDSmap)
- Number of HIV Regimens Linked to Lower Bone Mineral Density. (July 2013, Poz)
- Studies look at bone changes during second-line therapy, fractures, and HIV- and HCV-related bone loss. (July 2013, AIDSmap)
- Lower Baseline CD4 is Associated with Greater Loss of Bone Mineral Density after ART Initiation. (March 2013, NATAP)
- New Tenofovir Prodrug Shows Potency, Plus Better Kidney and Bone Safety Than Current Formulation. (March 2013, TheBodyPro)
- Peak Bone Mass Lower in Young HIV+ vs HIV- Men–and Bone Structure Abnormal. (March 2013, NATAP)
- New tenofovir prodrug virologically equivalent to TDF – and easier on kidneys and bone. (March 2013, NATAP)
- Frailty increases the risk of fragility fractures in men living with HIV: data collected in routine HIV care can help predict risk. (February 2013, AIDSmap)
- Co-infection with hepatitis B or C is a risk factor for reduced bone mineral density among women with HIV. (January 2013, AIDSmap)